Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
18 minutes. https://www.investorschronicle.co.uk/shares/2018/07/30/boardroom-talk-optibiotix/
Been in Optibiotix for some time. Now dipped a toe in this, will top up if it drifts back.
I wouldn't take any notice of the buying/selling volumes, they're often incorrect. Most here are in for the long term . I suspect by the end of the year this will be at least back to where the price was in January.
Chi-Med is one of Investors Chronicle's Tips of the week in the issue out tomorrow. Below is just the summary. See a hard copy for the rest. I'm a subscriber so receive emails during the week. With its plethora of near-term catalysts, excellent long-term outlook and strong financial position, Chi-Med is a rarity in the mid-sized biopharma world. Pre-tax profits may not be forecast until 2021, but the volume of clinical updates in the coming years, alongside the forecast growth in the Chinese commercial business, makes us confident that the share price will continue to climb. Buy.